A Patient's Cure, A Doctor's Hope: TIME Honors New Cancer Therapy

NEW YORK, NY – February 11, 2026 – In an acknowledgment that merges the pinnacle of scientific innovation with its profound human impact, TIME magazine has named University of Minnesota researcher Dr. Emil Lou and his patient, Emma Weston-Dimery, to its prestigious 2026 TIME100 Health list. The joint recognition celebrates a groundbreaking clinical trial that has not only rendered Weston-Dimery cancer-free after a grueling battle with metastatic colorectal cancer but also signals a new frontier in the fight against solid tumors.

Dr. Lou, a Professor of Medicine at the Masonic Cancer Center, served as the Principal Investigator for a first-in-human study sponsored by Intima Bioscience. The trial tested a novel immunotherapy that targets a previously "undruggable" intracellular protein. Weston-Dimery, who enrolled in the trial in 2023 as a last resort, is now living without evidence of the disease, a testament to the therapy's potential and a beacon of hope for countless others.

From Stage 4 to a Symbol of Hope

Emma Weston-Dimery's story is one of remarkable resilience. Diagnosed with colon cancer at just 23, she spent over a decade navigating the arduous landscape of cancer treatment, cycling through multiple therapies as the disease relentlessly progressed to Stage 4.

"By the time I enrolled in Dr. Lou's clinical trial in 2023, I had very few options left," Weston-Dimery stated in a press release. Her case was challenging; the cancer had proven resistant to standard-of-care chemotherapy and existing immunotherapies. For patients like her, the path forward often narrows to a horizon of limited and diminishing hope.

Everything changed after she received the investigational treatment developed by Intima Bioscience. The therapy, which involves genetically editing a patient's own immune cells, prompted a complete clinical response. Today, more than three years later, she remains cancer-free. "Today, I'm cancer-free," she shared. "I'm deeply thankful to Dr. Lou, the Intima Bioscience team, and everyone who stood by me and the other trial participants along the way. It's an honor to be recognized by TIME100 Health."

Her journey from a terminal diagnosis to a celebrated survivor on a global stage powerfully illustrates the life-altering potential of cutting-edge clinical research and has become a focal point in the discussion around new cancer cures.

Hacking the Immune System: Targeting CISH

The science behind Weston-Dimery's recovery represents a significant paradigm shift in immuno-oncology. For years, the most successful immunotherapies, known as checkpoint inhibitors, have worked by blocking proteins on the surface of immune cells, such as PD-1. These surface proteins act as brakes that prevent the immune system from attacking cancer. Releasing these brakes can be highly effective, but not for all patients or all cancers.

Intima Bioscience's approach goes deeper—literally. The therapy targets a protein inside the T cell called CISH (Cytokine-inducible SH2-containing protein). CISH functions as a master intracellular checkpoint, a hidden brake that negatively regulates the T cell's ability to recognize and attack cancer cells. Because it resides within the cell, it has long been considered a "traditionally undruggable" target for conventional drug development.

In the clinical trial, researchers used CRISPR gene-editing technology to remove, or "knock out," the CISH gene from a patient's own tumor-infiltrating T cells. These re-engineered cells, now free from their internal brake, are infused back into the patient, programmed for a more robust and effective anti-tumor assault.

"In partnership with Intima Bioscience, we are developing an investigational immunotherapy that programs patients' own T cells to mount a more effective anti-tumor response, offering a potential new path for patients whose cancer doesn't respond to existing treatments," explained Dr. Lou. The success of the trial, whose data was presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting and published in The Lancet Oncology, provides a critical proof-of-concept for this innovative strategy.

A Growing Crisis Meets a New Weapon

The timing of this breakthrough is particularly critical. Dr. Lou noted the alarming trend of rising colorectal cancer rates among young adults, a phenomenon that has puzzled epidemiologists. According to the American Cancer Society, early-onset colorectal cancer—diagnosed in those under 50—has been increasing since the mid-1990s. It is projected that within a decade, 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in this younger demographic.

This disturbing trend creates a pressing unmet medical need for more effective and durable treatments, as younger patients face the prospect of living with or dying from a disease once associated primarily with older age. The CISH-targeted therapy offers a new line of attack, especially for advanced and refractory cases that are becoming more common in this population.

"As advanced colorectal cancer rates continue to rise globally, particularly among young adults, we believe traditionally undruggable intracellular checkpoint targets like CISH now have dramatic anti-cancer potential," Dr. Lou commented. His work, amplified by Weston-Dimery's outcome, provides a crucial glimmer of hope against a backdrop of this growing public health crisis.

The Next Step: Democratizing a Cure

While the CRISPR-based cell therapy has proven its potential, it remains a complex and highly personalized procedure, limiting its accessibility. Recognizing this, Intima Bioscience is already working on the next evolution of its discovery: an oral small molecule drug.

This future therapy, described as a "molecular glue," is being designed to inhibit CISH function without the need for complex cell engineering and infusions. The development of a pill that can achieve the same powerful anti-tumor effect would revolutionize treatment accessibility, aligning with the company's mission to "democratize the promise of immunotherapy."

An oral medication could be administered to a much broader patient population globally, reducing the immense logistical and financial burdens associated with current cell therapies. It would transform a cutting-edge treatment from a specialized procedure available only at major medical centers into a therapy that could be prescribed to patients in a much wider variety of settings.

With a strong scientific foundation, validated by peer-reviewed publications in prestigious journals like Lancet Oncology and a Nature publication, and now recognized by TIME, the work pioneered by Dr. Lou and Intima Bioscience is paving a new path. It is a path defined not only by innovative science but by the tangible hope it offers to patients like Emma Weston-Dimery, who are living proof that even in the face of the most daunting diseases, the future of medicine is bright.